Thanks to Ben Gold for encouraging me to review this article:
RS Mehta et al. Gastroenterol 2023; ; 165: 564-572. Open Access! Association of Proton Pump Inhibitor Use With Incident Dementia and Cognitive Decline in Older Adults: A Prospective Cohort Study
The authors used data from ASPirin in Reducing Events in the Elderly (ASPREE), a randomized prospective trial of aspirin in the United States and Australia, including 18,934 community-based adults ≥65 years of all races/ethnicities (enrollment 2010-2014). Final cognitive testing was done in 2017. Key Findings:
- Baseline PPI use vs nonuse was not associated with incident dementia (multivariable hazard ratio, 0.88, cognitive impairment without dementia (multivariable hazard ratio, 1.00), or with changes in overall cognitive test scores over time.
- Also, no associations were observed between H2RA use and all cognitive endpoints.
My take: ” These data provide reassurance about the safety of long-term use of PPIs among older adults.” PPIs are unlikely to have negative effects on cognition.
Related blog posts:
- Austin Bradford Hill, PPIs and IBD
- Expert Advice: De-Prescribing Proton Pump Inhibitors
- Why Observational Studies Are Misleading & PPI Association with Kidney Stones
- PPIs: Good News on Safety
- PPIs: Good News on Safety (Part 2) | gutsandgrowth
- More Good News for PPIs: NO Increased Risk of Dementia
- Deconstructing PPI-Associated Risks with Nearly 8 Billion Data Points and More on COVID-19 GI Symptoms (Video) | gutsandgrowth
- PPI Side Effects: “Dissecting the Evidence” | gutsandgrowth















